MaaT Pharma commences HERACLES Phase 2 trial for MaaT013 in battle against acute graft-versus-host disease
MaaT Pharma, a French oncology company, has announced a significant milestone in its clinical research: the dosing of the first patient in the HERACLES Phase 2 trial for MaaT013, a microbiome restoration therapy. This trial targets steroid-resistant acute Graft-versus-Host-Disease (SR-aGvHD), a severe complication following allogeneic stem cell transplants. Acute Graft-versus-Host-Disease (aGvHD) is a major cause […]